Pfizer Says FDA Approved ABRYSVO, Its Vaccine For Prevention Of Respiratory Syncytial Virus (RSV) In Infants Through Active Immunization Of Pregnant Individuals 32-36 Weeks Of Gestational Age
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Pfizer's ABRYSVO, a vaccine for the prevention of Respiratory Syncytial Virus (RSV) in infants. The vaccine works through active immunization of pregnant individuals between 32-36 weeks of gestational age.
August 21, 2023 | 9:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's ABRYSVO vaccine has received FDA approval, potentially opening a new revenue stream for the company.
The FDA approval of Pfizer's ABRYSVO vaccine is a significant milestone for the company. This could potentially open a new revenue stream for Pfizer, as RSV is a common cause of respiratory illness worldwide. The news is likely to be viewed positively by the market, potentially leading to a short-term increase in Pfizer's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100